Colorectal Cancer
Conditions
Interventions
None listed
Sponsors
St. Marianna University School of Medicine
Kinki University School of Medicine, Department of Genome Biology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patient with histologically confirmed primary adenocarcinoma. 2)Patient with advanced or recurrent colorectal carcinoma. 3)Patient with KRAS exon2 codon12/13 wild colorectal cancer. 4)Patient with lesion confirmed by imaging tests before chemotherapy. 5)Patient with metastatic colorectal cancer with measurable lesion according to RECIST ver.1.1 6)Patients who plan to receive chemotherapy including anti-EGFR antibody. 7)Patients who plan to receive imaging tests within 3 months after commencement of chemotherapy. 8)Age over 20. 9)Patient with metastatic colorectal cancer whose paraffin-embedded samples were obtained enough at St Marianna University School of Medicine Hospital . 10) Patient with written informed consent. 11) Patient who can provide bloody specimens before chemotherapy.
Exclusion criteria
Exclusion criteria: 1) Patient with simultaneous or metachronous double cancers except carcinoma in situ or intramucosal tumor. 2) Patient with active bacterial or fungous infection. 3) Patient with uncontrollable pleural effusion or ascites. 4) Patient with history of interstitial neumonitis to pulmonary fibrosis. 5) Other patients who were considered by the primary care physician to be inappropriate as subjects of this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence and location of gene mutation corresponding to response to anti-EGFR antibody | — |
Countries
Japan
Contacts
Public ContactTakuro Mizukami
St. Marianna University School of Medicine Department of clinical oncology
Outcome results
None listed